Publications
Outcomes in patients undergoing hematopoietic stem cell transplantation for myelodysplastic syndromes
Sujith Karumathil 1, Uday Kulkarni 1, Sushil Selvarajan 1, Sharon Lionel 1, Anup J Devasia 1, Fouzia N Aboobacker 1, Kavitha M Lakshmi 1, Anu Korula 1, Alok Srivastava 1, Aby Abraham 1, Vikram Mathews 1, Biju George 1 Hematopoietic stem cell transplantation [HSCT] is the only curative option for patients with myelodysplastic syndromes [MDS]. Between 1991 and 2021, 154 patients [high risk, 86; low risk, 68] including 22 children underwent HSCT with a median age of 36 years. Conditioning regimens were myeloablative [n=97] and reduced intensity [n=53]. Donors were human leucocyte antigen (HLA)-matched related donors (MRDs) in 113 and alternate donors in 41. The graft source was peripheral blood stem cells in 92%.